Molecular Evolutionary Patterns in Breast Cancer
暂无分享,去创建一个
[1] Albert J. Fornace,et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.
[2] P. Diest,et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade , 2001, The Journal of pathology.
[3] K. Fukasawa,et al. p53 Mutation and Mitotic Infidelity , 2000, Cancer investigation.
[4] S. Petruolo,et al. Aneuploidy in breast cancer: a fluorescence in situ hybridization study. , 1995, Cytometry.
[5] M. Greene,et al. Genetics of breast cancer. , 1997, Mayo Clinic proceedings.
[6] M. Stratton,et al. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[7] Gustavo Droguett,et al. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation , 2000, Nature Cell Biology.
[8] J Isola,et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization , 1997, International journal of cancer.
[9] F. Schmitt,et al. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c‐erbB‐2 protein , 1995, Cancer.
[10] P. V. van Diest,et al. Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer. , 1998, Molecular pathology : MP.
[11] W. Gullick,et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. , 1991, Cancer research.
[12] C. Sherr. The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.
[13] R. Xu,et al. Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material , 2002, Modern Pathology.
[14] J. Myles,et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. , 2002, American journal of clinical pathology.
[15] G. Moreno-Bueno,et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas , 2002, Oncogene.
[16] T. Sofuni,et al. Illegitimate recombination leading to allelic loss and unbalanced translocation in p53-mutated human lymphoblastoid cells , 1997, Molecular and cellular biology.
[17] S. Hirohashi,et al. p53 Mutations and c‐erbB‐2 Amplification in Intraductal and Invasive Breast Carcinomas of High Histologic Grade , 1993, Japanese journal of cancer research : Gann.
[18] S. Devries,et al. Genomic alterations in tubular breast carcinomas. , 2001, Human pathology.
[19] Takafumi Nishizaki,et al. Genetic alterations in primary breast cancers and their metastases: Direct comparison using modified comparative genomic hybridization , 1997, Genes, chromosomes & cancer.
[20] J. Soares,et al. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. , 1999, Journal of clinical pathology.
[21] F. Sarkar,et al. Correlation of DNA ploidy with c-erbB-2 expression in preinvasive and invasive breast tumors. , 1991, Analytical and quantitative cytology and histology.
[22] H Buerger,et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes , 1999, The Journal of pathology.
[23] D. Pinkel,et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[24] R. Jove,et al. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors , 1999, Oncogene.
[25] W. McGuire,et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.
[26] H. Frierson. Grade and flow cytometric analysis of ploidy for infiltrating ductal carcinomas. , 1993, Human pathology.
[27] N. Rosen,et al. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.
[28] G. Cserni. Complete sectioning of axillary sentinel nodes in patients with breast cancer. Analysis of two different step sectioning and immunohistochemistry protocols in 246 patients , 2002, Journal of clinical pathology.
[29] W. McGuire,et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. , 1992, Journal of the National Cancer Institute.
[30] D. Spandidos,et al. Expression of ras Rb1 and p53 proteins in human breast cancer. , 1992, Anticancer research.
[31] M. Wigler,et al. Signaling pathways in Ras-mediated tumorigenicity and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Shackney,et al. Model for the genetic evolution of human solid tumors. , 1989, Cancer research.
[33] S. Hirohashi,et al. Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c‐erbB‐2 expression patterns in both the non‐invasive and invasive portions , 1998, Pathology international.
[34] D. Visscher,et al. Multiparametric deoxyribonucleic acid and cell cycle analysis of breast carcinomas by flow cytometry. Clinicopathologic correlations. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[35] Rochelle L. Garcia,et al. C‐ERBB‐2 oncogens protein in In situ and invasive lobular breast neoplasia , 1991 .
[36] Sam W. Lee,et al. Role of Pin1 in the Regulation of p53 Stability and p21 Transactivation, and Cell Cycle Checkpoints in Response to DNA Damage* , 2002, The Journal of Biological Chemistry.
[37] D. Persons,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[38] P. V. van Diest,et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution , 2001, The Journal of pathology.
[39] F. Smith,et al. Relationships between image cytometric DNA index, proliferation fraction and multiploidy and conventional nuclear grade in breast carcinoma. , 1993, Modern Pathology.
[40] A. Reiner,et al. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients , 2005, Journal of Cancer Research and Clinical Oncology.
[41] V. Keshamouni,et al. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion , 2001, Oncogene.
[42] E. Campo,et al. CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS , 1997, The Journal of pathology.
[43] Jiri Bartek,et al. Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.
[44] C. Prives,et al. The p53 pathway , 1999, The Journal of pathology.
[45] M. J. van de Vijver,et al. © 1997 Cancer Research Campaign , 2022 .
[46] N. Sneige,et al. Molecular and Biologic Markers of Premalignant Lesions of Human Breast , 2002, Advances in anatomic pathology.
[47] I. Bièche,et al. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer , 2000, Molecular carcinogenesis.
[48] W. Sauerbrei,et al. DNA flow cytometry in node-positive breast cancer. Prognostic value and correlation with morphologic and clinical factors. , 1995, Analytical and quantitative cytology and histology.
[49] D. Horsfall,et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] M. Press,et al. p53 mutations and expression in breast carcinoma in situ. , 2000, The American journal of pathology.
[51] W. Cavenee,et al. Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. , 1992, Human pathology.
[52] T. Oyama,et al. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. , 1998, Cancer research.
[53] P. V. van Dam,et al. Flow cytometric detection of multifocal DNA aneuploid cell populations in mastectomy specimens containing a primary breast carcinoma. , 1990, Cytometry.
[54] M. Osborn,et al. Immunohistochemical profile of invasive lobular carcinoma of the breast: Predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive , 2005, Virchows Archiv A.
[55] S. Ménard,et al. Role of p53 in HER2-induced Proliferation or Apoptosis* , 2001, The Journal of Biological Chemistry.
[56] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[57] S. Nordling,et al. Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. , 1997, Acta oncologica.
[58] S. Ingvarsson,et al. Molecular genetics of breast cancer progression. , 1999, Seminars in cancer biology.
[59] W. Birchmeier,et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. , 1993, The American journal of pathology.
[60] E. Fearon,et al. The SLUG zinc-finger protein represses E-cadherin in breast cancer. , 2002, Cancer research.
[61] G. Berx,et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. , 1996, Oncogene.
[62] J. Cunningham,et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. , 1995, Oncogene.
[63] T. Julian,et al. Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. , 2001, Cytometry.
[64] S E Shackney,et al. The accumulation of multiple genetic abnormalities in individual tumor cells in human breast cancers: clinical prognostic implications. , 1996, The cancer journal from Scientific American.
[65] G. Wahl,et al. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[66] G. Divine,et al. Two-color, cytokeratin-labeled dna flow cytometric analysis of 332 breast cancers: lack of prognostic value with 12-year follow-up. , 2001, Archives of pathology & laboratory medicine.
[67] J F Silverman,et al. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[68] S. Hirohashi,et al. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. , 1996, Oncogene.
[69] K. Hirata,et al. Detection of p53 gene mutations in fine-needle aspiration biopsied breast cancer specimens: correlations with nuclear p53 accumulations and tumor DNA aneuploidy patterns. , 1997, Cancer letters.
[70] Persons Dl,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .
[71] P. Diest,et al. Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material: Correlations between flow cytometric, clinical, and pathologic variables , 1996 .
[72] H. Moch,et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.
[73] H. Olsson,et al. Correlation between karyotypic pattern and clinicopathologic features in 125 breast cancer cases , 1996, International journal of cancer.
[74] L. Melton,et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] M. Oren,et al. Regulation of p53 , 2002, Annals of the New York Academy of Sciences.
[76] I. Nenci,et al. Biological profile of in situ breast cancer investigated by immunohistochemical technique. , 1998, Cancer detection and prevention.
[77] W. Gregory,et al. The classification of ductal carcinoma in situ and its association with biological markers. , 1994, Seminars in diagnostic pathology.
[78] N. Goldstein,et al. Intraductal carcinoma associated with invasive carcinoma of the breast. A comparison of the two lesions with implications for intraductal carcinoma classification systems. , 1996, American journal of clinical pathology.
[79] T. Visakorpi,et al. Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.
[80] Jose M. Silva,et al. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer , 2001, Oncogene.
[81] L. Norton,et al. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] F. Mitelman,et al. Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients , 1998, Genes, chromosomes & cancer.
[83] E. Kawasaki,et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.
[84] Patrick E Carroll,et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression , 1999, Oncogene.
[85] J. D. Weber,et al. The ARF/p53 pathway. , 2000, Current opinion in genetics & development.
[86] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[87] S. Hirohashi,et al. Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[88] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] A. Hanby,et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. , 1999, Cancer research.
[90] B. Angus,et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study , 1992, The Journal of pathology.
[91] L. Donehower. Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. , 1996, Biochimica et biophysica acta.
[92] N. Phillips,et al. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.
[93] A. Schäffer,et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. , 1997, Cancer research.
[94] T. Rebbeck,et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. , 2001, American journal of clinical pathology.
[95] Thea D. Tlsty,et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.
[96] S. Devries,et al. Loss of chromosome 16q in lobular carcinoma in situ. , 2001, Human pathology.
[97] M. Stratton,et al. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. , 1995, Journal of clinical pathology.
[98] Hiroki Inui,et al. Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy , 1993, Breast Cancer Research and Treatment.
[99] S. Parsons,et al. Src family kinases and HER2 interactions in human breast cancer cell growth and survival , 2001, Oncogene.
[100] J. Coindre,et al. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases , 1995, Breast Cancer Research and Treatment.
[101] D. Davey,et al. Comparison of nuclear grade and DNA cytometry in breast carcinoma aspirates to histologic grade in excised cancers. , 1993, American journal of clinical pathology.
[102] M. Melamed,et al. Flow cytometry of breast carcinoma: I. Relation of DNA ploidy level to histology and estrogen receptor , 1981, Cancer.
[103] C. Yue,et al. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene , 2001, Oncogene.
[104] E. Gabrielson,et al. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. , 1996, Cancer research.
[105] I. Andrulis,et al. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. , 1998, Cancer research.
[106] J. Isola,et al. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. , 2001, Cancer research.
[107] L. Holmberg,et al. Ductal Carcinoma in Situ of the Breast: a New Phenotype Classification System and its Relation to Prognosis , 2002, Breast Cancer Research and Treatment.
[108] A. Levine,et al. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[109] F. Alt,et al. Unrepaired DNA Breaks in p53-Deficient Cells Lead to Oncogenic Gene Amplification Subsequent to Translocations , 2002, Cell.
[110] A. Zetterberg,et al. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. , 1994, Human pathology.
[111] J. Schneider,et al. Histological Grade in Breast Cancer: Association with Clinical and Biological Features in a Series of 229 Patients , 2001, The International journal of biological markers.
[112] Ook Joon Yoo,et al. Methylation in the p53 Promoter Is a Supplementary Route to Breast Carcinogenesis: Correlation between CpG Methylation in the p53 Promoter and the Mutation of the p53 Gene in the Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma , 2001, Laboratory Investigation.
[113] R. Ridolfi,et al. HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach , 2000, Modern Pathology.
[114] A. Marchetti,et al. Cyclin‐d1‐gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 immunohistochemical expression , 1997, International journal of cancer.
[115] K. Lee,et al. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast , 2001, The Journal of pathology.
[116] A. Lazaris,et al. PROGNOSTIC SIGNIFICANCE OF THE CO‐EXPRESSION OF p53 AND c‐erbB‐2 PROTEINS IN BREAST CANCER , 1996, The Journal of pathology.
[117] F. Speleman,et al. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer , 1997, Virchows Archiv.
[118] M. Gnant,et al. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. , 1997, European journal of cancer.
[119] G. Wahl,et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.
[120] M. Oren,et al. Regulation of p53: intricate loops and delicate balances. , 2002, Biochemical pharmacology.
[121] B. Lloveras,et al. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[122] J. Niland,et al. The MDM2 gene amplification database. , 1998, Nucleic acids research.
[123] J. Schlom,et al. Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. , 1986, Cancer research.
[124] Tianhua Niu,et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c‐Jun towards cyclin D1 , 2001, The EMBO journal.
[125] A. Marchetti,et al. p53 Mutations and Histologie Type of Invasive Breast Carcinoma , 1993, Cancer research.
[126] S. Naber,et al. Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. , 2000, Cancer research.
[127] M. Stenmark-Askmalm,et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. , 1994, European journal of cancer.
[128] S Toikkanen,et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] R. Simon,et al. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast , 2000, Molecular pathology : MP.
[130] A. Vincent-Salomon,et al. Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns , 1996, Cancer.
[131] G. Tamura,et al. Epithelial‐cadherin Gene Is Not Mutated in Ductal Carcinomas of the Breast , 1995, Japanese journal of cancer research : Gann.
[132] E. Frenkel,et al. Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status , 2002, Modern Pathology.
[133] O. Kallioniemi,et al. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry , 1990, Cancer.
[134] L. Bonetta,et al. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. , 1994, Oncogene.
[135] N. Hellyer,et al. Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor* , 2001, The Journal of Biological Chemistry.
[136] M. Pagano,et al. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression. , 1994, Oncogene.
[137] P. Steeg,et al. Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity , 2004, Breast Cancer Research and Treatment.
[138] W. Lee,et al. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. , 1988, Science.
[139] P. Steeg,et al. Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. , 1996, The American journal of pathology.
[140] D K Gaffney,et al. Pathobiologic characteristics of hereditary breast cancer. , 1998, Human pathology.
[141] S. Devries,et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[142] D. Horsfall,et al. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[143] L. Neckers,et al. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. , 2001, Cancer research.
[144] I. Macdonald,et al. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. , 2002, Cancer research.
[145] D. Birnbaum,et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. , 1994, British Journal of Cancer.
[146] C. Benz,et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. , 1989, Cancer research.
[147] I. Ellis,et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.
[148] N. Phillips,et al. Allelic loss and the progression of breast cancer. , 1995, Cancer research.
[149] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[150] R. Millikan,et al. p53 mutations in benign breast tissue. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[151] C. Redmond,et al. DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S‐Phase fraction to outcome of patients in NSABP B‐04 , 1991, Cancer.
[152] D. Barnes,et al. Tumour grade does not change between primary and recurrent mammary carcinoma. , 1998, European journal of cancer.
[153] U. Lehmann,et al. Amplification of Growth Regulatory Genes in Intraductal Breast Cancer Is Associated with Higher Nuclear Grade but Not with the Progression to Invasiveness , 2001, Laboratory Investigation.
[154] D. Visscher,et al. Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast. , 1990, Archives of pathology & laboratory medicine.
[155] G. Cserni,et al. Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma. , 2002, Journal of Clinical Pathology.
[156] S. Hirohashi,et al. c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. , 1995, Biochemical and biophysical research communications.
[157] J. Marks,et al. Overexpression of p53 and HER‐2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer , 1994, Annals of surgery.
[158] J. Peterse,et al. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type , 1999, British Journal of Cancer.
[159] P. O’Connell,et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.
[160] A. Leong,et al. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. , 2001, American journal of clinical pathology.
[161] F. King,et al. Hsp70 interactions with the p53 tumour suppressor protein , 2001, The EMBO journal.
[162] W. J. Brammar,et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. , 1989, Oncogene.
[163] J. Peterse,et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. , 1996, British Journal of Cancer.
[164] L. Gu,et al. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[165] S. Tsutsui,et al. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[166] S. Lakhani. The transition from hyperplasia to invasive carcinoma of the breast , 1999, The Journal of pathology.
[167] M. J. van de Vijver,et al. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast , 1999, The Journal of pathology.
[168] U. Lehmann,et al. Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. , 2002, Cancer research.
[169] G. Landberg,et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node , 2002, Oncogene.
[170] A. Patchefsky,et al. CCND1‐ and ERBB2‐gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast , 2002, Molecular carcinogenesis.
[171] P. Dalla Palma,et al. Cytometric DNA Analysis and Prognostic Biomarkers in Breast Carcinoma. Expression of P53 Product in the Different Ploidy Classes , 1997, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[172] R. Sutherland,et al. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[173] P. Sismondi,et al. c‐erbB‐2 and ras expression levels in breast cancer are correlated and show a co‐operative association with unfavorable clinical outcome , 1991, International journal of cancer.
[174] D. Germain,et al. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer , 1999, Oncogene.
[175] P. V. van Diest,et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. , 1997, The American journal of pathology.
[176] I. Ellis,et al. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. , 1992, British Journal of Cancer.
[177] S. Kamel,et al. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer , 1996, Journal of cellular biochemistry. Supplement.
[178] T. Shankey,et al. Common patterns of genetic evolution in human solid tumors. , 1997, Cytometry.
[179] W. El-Deiry. p21/p53, cellular growth control and genomic integrity. , 1998, Current topics in microbiology and immunology.
[180] C. Shimizu,et al. c‐erbB‐2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues , 2000, Journal of surgical oncology.
[181] A. Cleton-Jansen. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? , 2001, Breast Cancer Research.
[182] C. Poremba,et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.
[183] G R Stark,et al. Regulation and mechanisms of mammalian gene amplification. , 1993, Advances in cancer research.
[184] N. Rosen,et al. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. , 2002, Cancer research.
[185] K. Vousden,et al. Regulation and function of the p53 tumor suppressor protein. , 2001, Current opinion in cell biology.
[186] P. Guldberg,et al. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients , 2000, Breast Cancer Research.
[187] G. Inghirami,et al. Tubular Carcinoma of the Breast: Immunohistochemical and DNA Flow Cytometric Profile , 1999, The breast journal.
[188] M L Agarwal,et al. The p53 Network* , 1998, The Journal of Biological Chemistry.
[189] P. V. van Diest,et al. Correlation of morphologic and cytogenetic parameters of genetic instability with chromosomal alterations in in situ carcinomas of the breast. , 2000, American journal of clinical pathology.
[190] W. Lewis,et al. Prognostic significance of flow cytometric DNA analysis in node‐negative breast cancer patients , 1990, Cancer.
[191] P. V. van Diest,et al. Genetic analysis of 53 lymph node‐negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors , 1998, The Journal of pathology.
[192] J. Bartek,et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. , 1993, European journal of cancer.
[193] S. Hirohashi,et al. Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. , 1997, Japanese journal of clinical oncology.
[194] M. Aapro,et al. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. , 1989, Cancer research.
[195] P. Devilee,et al. Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss , 1992, International journal of cancer.
[196] H. Sasano,et al. Immunolocalization of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human breast carcinoma. , 1997, Anticancer research.
[197] B. Iacopetta,et al. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[198] R. Soslow,et al. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas , 2000, Breast Cancer Research and Treatment.
[199] Kristen L Murphy,et al. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer , 2000, Oncogene.
[200] J. Bartek,et al. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity , 1995, Molecular and cellular biology.
[201] B. Dutrillaux,et al. Breast cancer genetic evolution: I. Data from cytogenetics and DNA content , 1991, Breast Cancer Research and Treatment.
[202] I. Ellis,et al. Prognostic significance of the DNA content of human breast cancer , 1987, The British journal of surgery.
[203] M. J. van de Vijver,et al. Simultaneous loss of E‐cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ , 1997, The Journal of pathology.
[204] F. O'Malley,et al. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. , 1997, The American journal of pathology.
[205] Y. Yarden,et al. Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.
[206] T. Crook,et al. The p53 pathway in breast cancer , 2002, Breast Cancer Research.
[207] O. Gröntoft,et al. Cytometric and histopathologic features of tumors detected in a randomized mammography screening program: Correlation and relative prognostic influence , 1990, Breast Cancer Research and Treatment.
[208] J. Sudbø,et al. Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.
[209] S. Hirohashi,et al. correlation between histologic grade of malignancy and copy number of c‐erbb‐2 gene in breast carcinoma. A retrospective analysis of 176 cases , 1990, Cancer.
[210] J. Eyfjörd,et al. p53 abnormalities and genomic instability in primary human breast carcinomas. , 1995, Cancer research.
[211] K. Weber,et al. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. , 1993, The American journal of pathology.
[212] C. Howe,et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. , 2001, Experimental and molecular pathology.
[213] P. Bontempo,et al. Estradiol induces functional inactivation of p53 by intracellular redistribution. , 2000, Cancer research.
[214] J. Biggart,et al. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. , 1992, Journal of clinical pathology.
[215] L. Holmberg,et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness , 2001, British Journal of Cancer.
[216] M. Merino,et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions , 1995, Nature Medicine.
[217] M. Kraus,et al. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. , 1990, Cancer research.
[218] S. Lowe,et al. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[219] F. Koerner,et al. Lobular Carcinoma in Situ and Infiltrating Ductal Carcinoma: Frequent Presence of DCIS as a Precursor Lesion , 2001, International journal of surgical pathology.
[220] T. Rohan,et al. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[221] E. Schröck,et al. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation , 1999, Genes, chromosomes & cancer.
[222] V. Kosma,et al. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. , 1995, European journal of cancer.
[223] J. Marks,et al. Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.
[224] J. Foekens,et al. Association between rb‐1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival , 1995, International journal of cancer.
[225] Bart,et al. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit , 1996, Molecular and cellular biology.
[226] J. Herman,et al. Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise. , 2000, Journal of the National Cancer Institute.
[227] G. Landberg,et al. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein , 1997, Oncogene.
[228] Yong-jie Lu,et al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. , 1998, Cancer research.
[229] S. Shackney,et al. Karyotypic evolution of a human undifferentiated large cell carcinoma of the lung in tissue culture. , 1989, Cancer research.
[230] D. Horsfall,et al. Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.
[231] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[232] M. Redston,et al. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. , 2001, Journal of the National Cancer Institute.
[233] G. Hortobagyi,et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[234] W. Dupont,et al. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[235] G. Serio,et al. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. , 1992, American journal of clinical pathology.